Lonza Backs Guidance Despite Soft Start to Year
By David Sachs
Lonza said its performance over the first quarter was soft but that it expects the first half to move in line with last year, and backed its full-year guidance.
The Swiss pharmaceutical company said Tuesday that it still expects flat sales growth at constant exchange rates for the year and core earnings before interest, taxes, depreciation and amortization margin in the high 20s.
Sales for the second half year are expected to be solid, reflecting the time of batch releases.
It didn't provide any actual figures for the first quarter.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 14, 2024 01:38 ET (05:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations